Pramipexole 2HCl Monohydrate

Pramipexole Dihydrochloride is a D2/3 agonist. It acts by reducing mitochondrial ROS production and inhibiting the activation of apoptotic pathways. (In Vitro) :Pramipexole dihydrochloride hydrate shows a low binding affinity for D1-type receptor, with an IC50 of >50,000 nM.Pramipexole dihydrochloride hydrate (0.01-10 μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size.Pramipexole dihydrochloride hydrate attenuates levodopa-induced toxicity in mesencephalic cultures. (In Vivo) :Pramipexole dihydrochloride hydrate (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals.Pramipexole dihydrochloride hydrate improves neurological recovery.Pramipexole dihydrochloride hydrate prevents ischemic cell death via mitochondrial pathways in ischemic stroke.